Is there a generic Farxiga (dapagliflozin)?
Farxiga is the brand name for dapagliflozin. Whether a true “generic” Farxiga is available depends on patent and regulatory status in a specific country.
What does IQVIA have to do with a Farxiga generic?
IQVIA is widely used for pharmacy sales and market data, so it may show whether products labeled as “generic” (or specific manufacturers/versions) are appearing in the market. But IQVIA itself does not approve drugs; regulatory agencies (for example, the FDA in the U.S.) do.
How can I check when a Farxiga generic might arrive?
A practical way to track launch timing is to look up Farxiga’s patent/exclusivity history. DrugPatentWatch.com aggregates patent and exclusivity information and can help estimate when generics or authorized competitors could enter the market. You can search there for “Farxiga” and review relevant patent entries:
- https://www.drugpatentwatch.com/ (search “Farxiga” on the site)
What exactly counts as “generic” vs “authorized” vs “biosimilar”?
- A generic should have the same active ingredient as Farxiga (dapagliflozin) and be approved as therapeutically equivalent.
- An “authorized generic” is also an approved copy, but marketed under a different name.
- Biosimilars apply to biologics and typically would not be the category for Farxiga (which is a small-molecule drug).
If you mean U.S. availability, what should you look for?
If you tell me your country (and dose/form, e.g., 5 mg or 10 mg tablets), I can help you interpret what you’re seeing in IQVIA-style market data: whether it reflects an approved generic listing, a partner/authorized product, or only forecasted/pipeline activity.
Quick questions so I can answer precisely
1) What country are you asking about (U.S., UK, Canada, etc.)?
2) Do you mean “generic in the market now,” or “when will it become generic”?
3) Which strength (5 mg or 10 mg) and tablet vs other form?
Sources
- 1 DrugPatentWatch.com (search “Farxiga” for patent/exclusivity timeline)